Comparison

Statins vs PCSK9 Inhibitors

Last updated Mon Jun 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time)· 2 min read

Mechanism

Statins: inhibit HMG-CoA reductase → upregulate hepatocyte LDL receptors → lower plasma LDL.
PCSK9 mAbs (evolocumab, alirocumab): neutralise circulating PCSK9 protein → reduce LDL-receptor degradation → lower LDL.
Inclisiran: siRNA that silences PCSK9 mRNA in hepatocytes; same final effect via different mechanism.

Outcomes evidence

Both classes are evidence-based. Major outcomes trials:

Statins: massive CTT meta-analysis (>200,000 patients) — ~20% relative CV event reduction per 1 mmol/L LDL lowering.
PCSK9 mAbs: FOURIER (evolocumab) and ODYSSEY OUTCOMES (alirocumab) showed ~15–20% relative CV event reduction on top of statin therapy in high-risk patients.
Inclisiran: ORION-4 cardiovascular outcomes trial reading out later this decade.

When statins are sufficient

For most adults with elevated apoB / LDL, a moderate-to-high-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) plus ezetimibe if needed brings LDL into target range. This is the standard first-line approach.

When PCSK9 inhibitors are added

Established ASCVD with LDL still above target on max statin + ezetimibe.
Familial hypercholesterolaemia (heterozygous or homozygous).
Statin intolerance (with verified inability to tolerate multiple statins).
Very high Lp(a) with apoB above target.

Side effects

Statins: ~5–10% report muscle symptoms in practice (SAMSON blinded RCT suggests most are nocebo); small new-onset diabetes risk (~1 per 1000 patient-years); rare hepatotoxicity.
PCSK9 mAbs: injection-site reactions; otherwise very clean safety profile in trials to date. No clear muscle, cognitive, cataract, or haemorrhagic-stroke signals.

Cost reality

Statins are essentially free (generic).
PCSK9 mAbs cost ~$5,000/year US list; insurance coverage requires documented criteria.
Inclisiran ~$3,250/dose, twice yearly, often cheaper than mAbs.

Which to choose

Primary prevention, average risk: statin alone.
Primary or secondary prevention not at target on statin alone: add ezetimibe.
Secondary prevention with persistent high apoB: add PCSK9 mAb or inclisiran.
Statin intolerance verified: ezetimibe + bempedoic acid; consider PCSK9 mAb.
Lp(a) very high: PCSK9 mAb may help (lowers Lp(a) ~25%).

The choice is rarely either/or; modern lipidology uses statins as the foundation and adds layers when needed.